<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CEFTRIAXONE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CEFTRIAXONE</h1>

        <p><a href="../drugClass/PHP34534.html">CEPHALOSPORINS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Surgical prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g for 1 dose, dose to be administered up to 30 minutes before procedure.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis before colorectal surgery</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2 g for 1 dose, dose to be administered up to 30 minutes before procedure, intramuscular doses over 1 g divided between more than one site.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Uncomplicated gonorrhoea</span>,
                <span class="indication">Pelvic inflammatory disease</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 mg for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Early syphilis</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 mg daily for 10 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2&#8211;4 g daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection or by intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g daily; increased to 2&#8211;4 g daily, increased dose to be used for severe infections, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Meningitis</span>,
            </h4>
            <p class="specificity"><span class="route">By deep intramuscular injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;11 years (body-weight up to 50 kg)</strong><br/>
                50&#8211;80 mg/kg daily, doses of 50 mg/kg and over to be administered by intravenous infusion only.</li>
              <li class="dose child"><strong>For children 1 month&#8211;11 years (body-weight 50 kg and above)</strong><br/>
                2&#8211;4 g daily, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                2&#8211;4 g daily, intramuscular doses over 1 g divided between more than one site, single intravenous doses above 1 g to be administered by intravenous infusion only.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of secondary case of meningococcal meningitis</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250 mg for 1 dose.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of secondary case of <ph outputclass="organism"> <i> <i>Haemophilus influenzae</i> </i> </ph> type b disease</span>,
            </h4>
            <p class="specificity"><span class="route">By intramuscular injection or by intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1 g daily for 2 days.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose if both hepatic and severe renal impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Reduce dose if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (max. 2&#8239;g daily).</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Max. 50&#8239;mg/kg daily (max. 2&#8239;g daily) in severe renal impairment.</p>
            </section>
        
            <section class="generalInformation">
              <p>Use with caution in renal failure.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li><strong>neonates:</strong> Concomitant treatment with intravenous calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks corrected gestational age&#8212;risk of precipitation in urine and lungs in neonates</li>
            <li><strong>neonates:</strong> neonates less than 41 weeks corrected gestational age in neonates</li>
            <li><strong>neonates:</strong> neonates over 41 weeks corrected gestational age with jaundice, hypoalbuminaemia, acidosis, unconjugated hyperbilirubinaemia, or impaired bilirubin binding in neonates</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Calcium ceftriaxone precipitates in gall bladder&#8212;consider discontinuation if symptomatic, calcium ceftriaxone precipitates in urine (particularly in very young, dehydrated or those who are immobilised)&#8212;consider discontinuation if symptomatic,
              </p>
              <p>
                <strong>rare:</strong> Pancreatitis, prolongation of prothrombin time,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous injection</i>, give over at least 2&#8211;4 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, dilute reconstituted solution with Glucose 5% or 10% <i>or</i> Sodium Chloride 0.9%; give over at least 30 minutes (60 minutes in neonates).</p><p>Not to be given simultaneously with parenteral nutrition or infusion fluids containing calcium, even by different infusion lines; may be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.</p><p>Displacement value may be significant, consult local guidelines.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use in children</h3>
              <p>For <i>intramuscular injection</i> ceftriaxone may be mixed with 1% Lidocaine Hydrochloride Injection to reduce pain at intramuscular injection site; final concentration 250&#8211;350&#8239;mg/mL. Displacement value may be significant, consult local guidelines.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Rocephin</i>
            <tm tmtype="reg"/>; <i>Ceftriaxone Injection</i>, Genus), give intermittently <i>or via</i> drip tubing <i>in</i> Glucose 5% or 10% <i>or</i> Sodium chloride 0.9%.</p><p>Reconstitute 2-g vial with 40&#8239;mL infusion fluid. Give by intermittent infusion over at least 30 minutes (60 minutes in neonates).</p><p>Not to be given simultaneously with total parenteral nutrition or infusion fluids containing calcium, even by different infusion lines. May be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.</p>
            </section>
      </section>




      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Dehydration (risk of ceftriaxone precipitation in gall bladder)
          </li>
          <li>
              <strong>:</strong>
            may displace bilirubin from serum albumin, administer over 60 minutes in neonates in neonates
          </li>
          <li>
            treatment longer than 14 days
          </li>
          <li>
              <strong>:</strong>
            use with caution in neonates in neonates
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Not licensed for prophylaxis of meningococcal meningitis or <i>Haemophilus influenzae</i> type b disease.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for congenital gonococcal conjunctivitis or early syphilis.</p><p>Not licensed for use in children under 12 years of age for uncomplicated gonorrhoea or pelvic inflammatory disease.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Not licensed for early syphilis.</p><p>Not licensed for endocarditis caused by haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella species ('HACEK organisms') (in combination with another antibacterial).</p><p>Dose not licensed for treatment of uncomplicated gonorrhoea or pelvic inflammatory disease in adults over 18 years.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CEFTRIAXONE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            infusion,

            <div id="PHP76112"><a href="../medicinalForm/PHP76112.html" data-target="#PHP76112" data-action="load">Powder for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
